undamentalytics Newsletter
Sign in

Kymera Therapeutics, Inc. revenue

Kymera Therapeutics, Inc.'s revenue was $39.2m in fiscal 2025, down 16.7% on the year before. Since fiscal 2019 ($2.9m) it has grown at a compound 54.0% a year. Over the last twelve months it was $102m.

Revenue history

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMSept 2026
Revenue3347347794739102
Growth on the year before—+>999%+114.0%−35.7%+67.8%−40.1%−16.7%—
Gross profit———00000
Gross margin———0.0%0.0%0.0%0.0%0.0%

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Revenue against peers

Biotechnology: the closest covered companies by revenue. Last twelve months.

CompanyRevenueGrowth3-year growth a year
Kymera Therapeutics, Inc. $102m 133.8% 29.7%
Xencor Inc $105m -28.6% -2.5%
Septerna, Inc. $98.9m 13520.1% —
Agios Pharmaceuticals, Inc. $98.3m 140.6% 69.6%
4d Molecular Therapeutics, Inc. $92.0m 278712.1% 242.8%
ARS Pharmaceuticals, Inc. $117m 4.1% 711.3%

Compare with peers

Head to head: KYMR vs XNCRKYMR vs SEPNAGIO vs KYMR

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Kymera Therapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved October 30, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Kymera Therapeutics, Inc.